Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology

New super-sensitive biomarker assay platforms for measuring Alzheimer’s disease (AD) core pathological markers in plasma have recently been developed and tested. Research findings from these technologies offer promising evidence for identifying the earliest stages of AD and correlating them with bra...

Descripción completa

Detalles Bibliográficos
Autores principales: Lue, Lih-Fen, Kuo, Yu-Min, Sabbagh, Marwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6908530/
https://www.ncbi.nlm.nih.gov/pubmed/31833027
http://dx.doi.org/10.1007/s40120-019-00167-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6908530/
https://www.ncbi.nlm.nih.gov/pubmed/31833027
http://dx.doi.org/10.1007/s40120-019-00167-2

Ejemplares similares